Lacosamide as treatment of epileptic seizures - cost utility results for Sweden.
Publikation/Tidskrift/Serie: Acta neurologica Scandinavica
Bolin K, Berggren F, Forsgren L. Lacosamide as treatment of epileptic seizures - cost utility results for Sweden. Acta Neurol Scand: DOI: 10.1111/j.1600-0404.2009.01320.x. (c) 2010 The Authors Journal compilation (c) 2010 Blackwell Munksgaard. Objectives - To calculate cost per additional quality-adjusted life-year (QALY) for lacosamide as adjunctive treatment for patients with uncontrolled partial-onset seizures as compared to no adjunctive treatment. Materials and methods - A decision-tree simulation model was constructed to calculate the number of seizures and health-care utilization for treated and untreated with lacosamide, respectively. Prices from 2007 were used for all costs. Results - All results were calculated for a 24-, 18-, 12- and 6-months follow-up. The cost per additional QALY was estimated to euro 27,641 (24 months). Using a willingness-to-pay threshold for a QALY of euro 50,000 the net marginal value of using lacosamide was estimated to about euro 850,000 per 1000 patients. Conclusions - The estimated cost per QALY gained falls within the range of reported estimates of the willingness-to-pay for an additional QALY. The results imply that lacosamide is cost-effective in the treatment of uncontrolled partial-onset seizures (1 euro approximately 9.6 SEK).
- ISSN: 1600-0404